| Target Price | $29.58 |
| Price | $17.49 |
| Potential |
69.13%
register free of charge
|
| Number of Estimates | 19 |
|
19 Analysts have issued a price target Nurix Therapeutics Inc 2027 .
The average Nurix Therapeutics Inc target price is $29.58.
This is
69.13%
register free of charge
$43.05
146.14%
register free of charge
$15.15
13.38%
register free of charge
|
|
| A rating was issued by 23 analysts: 21 Analysts recommend Nurix Therapeutics Inc to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Nurix Therapeutics Inc stock has an average upside potential 2027 of
69.13%
register free of charge
|
| Nov '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 54.55 | 86.95 |
| 29.15% | 59.40% | |
| EBITDA Margin | -373.44% | -300.23% |
| 94.88% | 19.60% | |
| Net Margin | -354.85% | -283.92% |
| 89.79% | 19.99% |
19 Analysts have issued a sales forecast Nurix Therapeutics Inc 2025 . The average Nurix Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Nurix Therapeutics Inc EBITDA forecast 2025. The average Nurix Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
19 Nurix Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Nurix Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Nov '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.88 | -3.21 |
| 8.68% | 11.46% | |
| P/E | negative | |
| EV/Sales | 15.46 |
19 Analysts have issued a Nurix Therapeutics Inc forecast for earnings per share. The average Nurix Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Nurix Therapeutics Inc...
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Wells Fargo |
Locked
➜
Locked
|
Locked | Dec 16 2025 |
| Mizuho |
Locked
➜
Locked
|
Locked | Dec 10 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 10 2025 |
| BTIG |
Locked
➜
Locked
|
Locked | Dec 09 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Dec 08 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Nov 04 2025 |
| BTIG |
Locked
➜
Locked
|
Locked | Nov 04 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Dec 16 2025 |
|
Locked
Mizuho:
Locked
➜
Locked
|
Dec 10 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 10 2025 |
|
Locked
BTIG:
Locked
➜
Locked
|
Dec 09 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Dec 08 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Nov 04 2025 |
|
Locked
BTIG:
Locked
➜
Locked
|
Nov 04 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


